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ABSTRACT
The signaling lymphocyte activation molecule family [SLAMF] of cell surface 
receptors partakes in both the development of several immunocyte lineages and innate 
and adaptive immune responses in humans and mice. For instance, the homophilic 
molecule SLAMF6 (CD352) is in part involved in natural killer T cell development, but 
also modulates T follicular helper cell and germinal B cell interactions. Here we report 
that upon transplantation of a well-defined aggressive murine B220+CD5+ Chronic 
Lymphocytic Leukemia (CLL) cell clone, TCL1-192, into SCID mice one injection of a 
monoclonal antibody directed against SLAMF6 (aSlamf6) abrogates tumor progression 
in the spleen, bone marrow and blood. Similarly, progression of a murine B cell 
lymphoma, LMP2A/lMyc, was also eliminated by aSlamf6. But, surprisingly, aSLAMF6 
neither eliminated TCL1-192 nor LMP2A/lMyc cells, which resided in the peritoneal 
cavity or omentum. This appeared to be dependent upon the tumor environment, 
which affected the frequency of sub-populations of the TCL1-192 clone or the inability 
of peritoneal macrophages to induce Antibody Dependent Cellular Cytotoxicity 
(ADCC). However, co-administering aSlamf6 with the Bruton tyrosine kinase (Btk) 
inhibitor, ibrutinib, synergized to efficiently eliminate the tumor cells in the spleen, 
bone marrow, liver and the peritoneal cavity. Because an anti-human SLAMF6 mAb 
efficiently killed human CLL cells in vitro and in vivo, we propose that a combination 
of aSlamf6 with ibrutinib should be considered as a novel therapeutic approach for 
CLL and other B cell tumors.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most 
common B cell leukemia in adults and is characterized 
by the accumulation of CD19+CD5+CD23+ B cells in the 
bone marrow, blood and secondary lymphoid organs [1]. 
Survival and proliferation of these tumors depend on two 
main factors: the tumor microenvironment and B cell 
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receptor (BCR) signaling [2, 3]. Within CLL “proliferation 
centers”, tumor cells interact with monocyte derived 
nurse-like cells (NLCs) [2–6], which provide survival 
signals via secretion of chemokines and cytokines [7, 8], 
or interacting cell surface receptor-ligand structures. The 
latter include CD74/MIF, CD84 (SLAMF5) and CD150 
(SLAMF1) [9–11].
Here we evaluate the efficacy of monoclonal 
antibodies directed against mouse and human SLAMF6 
(CD352) in CLL prognosis. SLAMF6 [12] is a homophilic 
SLAMF receptor [13–22], which plays a key role in the 
interactions between T follicular helper (TFH) cells and 
Germinal Center B (GCB) cells [19, 23–32]. To study the 
effect of anti-SLAMF6 on tumor progression we use the 
aggressive transplantable murine CLL clone TCL1-192 
and the B cell lymphoma LMP2A/λMyc [33–35] into 
SCID or Rag1−/− mice, respectively. The murine TCL1-192 
clone expresses a B cell receptor with a single IGHV-D-J 
arrangement, which is specific for phosphatidyl choline 
[PtC], has many characteristics in common with human 
CLL cells [33]. As the transfer of TCL1-192 into SCID 
mice leads to an aggressive disease progression within 
5-6 weeks, this offers a very useful platform to identify 
relevant potential therapeutic targets [33].
The data indicate that removal of the tumor cells by 
a mouse anti- mouse Slamf6 (αSlamf6) antibody (13G3) 
[26], see Materials and Methods) relies on antibody 
dependent cell-mediated cytotoxicity (ADCC) and co-
stimulation of B cell receptor (BCR) signaling, which is 
of importance to progression of CLL. Co-administering 
αSlamf6 with the Bruton tyrosine kinase (Btk) inhibitor 
ibrutinib has a synergistic effect on treatment of the 
tumors. Furthermore, we provide evidence that mouse 
anti-human SLAMF6 (αhSLAMF6) antibody is efficient 
in in vitro and in vivo killing of two CLL cell lines MEC-1 
and OSU-CLL [36, 37].
RESULTS
Administering αSlamf6 prevents expansion of 
TCL1-192 cells in the spleen and blood, but not 
in the peritoneal cavity
We first determined that surface expression of 
SLAMF receptors by TCL1-192 cells [33] is comparable 
to SLAMF surface expression by patient-derived human 
CLL cells and the CLL cell lines MEC1 and OSU-CLL 
(Supplementary Figure S1 and S2). Consistent with 
its high level of expression by B lineage cells [38], this 
SLAMF6 is found on the surface of freshly isolated human 
CLL cells (Supplementary Figure S1C) or frozen patient 
cells (Supplementary Figure S2). Whereas SLAMF6 
expression varies somewhat between CLL cells from 
different patients, SLAMF1 and SLAMF7 expression 
differs more between individual patients (Supplementary 
Figure S2). Similar to its relative expression by mouse B 
cells, (www.immgen.org) [26], Slamf6 is highly expressed 
on the surface of TCL1-192 cells. Surprisingly, the level of 
expression of Slamf6 on the surface of TCL1-192 cells in 
the peritoneal cavity was twice that on cells isolated from 
the blood or spleen (MFI P: 23739, B: 13279, S: 14384) 
(Supplementary Figure S1).
To assess the efficacy of αSlamf6 in preventing 
expansion of the mouse CLL cells, αSlamf6 IgG2a was 
administered on day 7, 14 and 21 post-transplant of the 
TCL1-192 cells into SCID mice (Figure 1A). Prior to 
these experiments we had determined that one week after 
injecting 0.5 × 106 TCL1-192 cells i.p. into a SCID mouse, 
the cells primarily reside in the peritoneal cavity, but that 
at day 28, the tumor cells have expanded and are found 
in the peritoneal cavity [~1 × 108], spleen [~4 × 108], 
and blood [~105/μl] (data not shown). Importantly, in a 
previous study a similar distribution of TCL1-192 cells 
was found regardless of whether the tumor cells were 
injected i.v. or i.p. [33].
At day 28 the spleen size of αSlamf6-treated mice 
was 20% of the spleen size of recipients of isotype-
control mice or of mice that had not received antibody 
(Figure 1B). More importantly, the number of leukemic 
cells in the spleen of recipients of αSlamf6 injected mice 
was 26 fold reduced (Figure 1C). TCL1-192 cells were 
virtually absent in the blood of αSlamf6-injected mice 
compared to the control mice (Figure 1D). Surprisingly, 
αSlamf6 did not affect the number of tumor cells in the 
peritoneal cavity (Figure 1E) or in the omentum, a well-
known reservoir for B1a cells [39] (Figure 1F). On day 
28 expression of Slamf6 by the leukemic cells in the 
peritoneal cavity, blood and spleen from all groups was 
comparable (Supplementary Figure S3A).
Together the data show that, three injections of 
αSlamf6 eliminated TCL1-192 cells in the spleen and 
blood of the recipient mice, but not in the peritoneal cavity.
Administering αSlamf6 reduced the number of 
LMP2A/λMyc B cell lymphomas in Rag-1−/− mice
To evaluate whether αSlamf6 would also 
effectively remove an unrelated CD19+B220+ murine 
B cell lymphoma, LMP2A/λMyc [35], which expresses 
Slamf6 (Figure 2A), on day 7 and 14 after i.p injection 
of LMP2A/λMyc [1 × 106 cells/mouse] into Rag1−/− 
mice, 200μg/mouse αSlamf6 or isotype control was 
administered (Figure 2B). On day 19 post-transplant 
αSlamf6 treated mice had significantly smaller spleens 
(Figure 2C) and less tumor cells than did control mice 
(Figure 2C and 2D). Thus, like in the case of the TCL1-
192 CLL cells, αSlamf6 also reduces the number 
LMP2A/λMyc lymphoma cells.
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Treatment with αSlamf6 after expansion of 
TCL1-192 cells in SCID mice
Next, we employed a “treatment protocol” to assess 
whether αSlamf6 would affect survival of SCID mice in 
which TCL1-192 cells had expanded for three weeks after 
transplant and antibodies were subsequently administered 
i.p. once a week (Figure 3A). While after 6 injections of 
αSlamf6 recipient mice were alive at day 60, the mice that 
had received control mIgG2a died between 35-42 days 
(Figure 3A).
Figure 1: Anti-Slamf6 prevents TCL1-192 expansion in the spleen and blood, but not in the peritoneal cavity, of SCID 
mice. A. Schematic outline of the prevention experiment. TCL1-192 cells were injected on d0 and 200μg mouse αSlamf6 (13G3) or a 
mouse IgG2a isotype control was injected i.p. into SCID mice on day 7, 14 and 21. Mice were sacrificed on day 28. B. Spleen size and 
weight at day 28. Administering αSlamf6 vs IgG2a isotype caused a 5.0- fold reduction (0.15 ± 0.02 vs. 0.78 ± 0.08 g; p = 0.0003) or 
5.8-fold reductions comparing αSlamf6 vs. no antibody (0.15 ± 0.02 vs. 0.87 ± 0.02 g; p < 0.0001). C. A 26-fold reduction of the number 
of TCL1-192 cells was detected in the spleen of αSlamf6-injected vs. non-injected (1.7 ± 0.8 × 107 vs. 4.4 ± 0.3 × 108 p < 0.0001); or 
29-fold in αSlamf6-injected vs. isotype-injected (1.7 ± 0.8 × 107 vs. 4.9 ± 0.7 × 108; p = 0.0008) SCID mice. Cells were gated on viable, 
DAPI−, B220+CD5+ cells. Counting beads were used to determine the number of TCL1-192 cells per μl of blood. D. A 113-fold reduction 
of TCL1-192 cells in the blood of αSlamf6-injected vs. non-injected mice was found (0.3 ± 0.1 × 103 vs. 3.4 ± 0.4 × 104 per μl blood; p = 
0.0003); 100-fold in αSlamf6-injected vs. isotype-injected mice (0.3 ± 0.1 × 103 vs. 3 ± 1.1 × 104 per μl blood; p = 0.047). E. Number of 
TCL1-192 cells in the peritoneal cavity: αSlamf6-injected vs. non-injected (9.38 ± 3.6 × 106 vs. 5.8 ± 2.3 × 106) or αSlamf6-injected vs. 
isotype-injected (9.38 ± 3.6 × 106vs. 1 ± 0.1 × 107). F. Number of TCL1-192 cells in the omentum: αSlamf6-injected vs. non-injected (9.5 
± 1.55 × 106 vs. 5.9 ± 1.2 × 106 or αSlamf6-injected vs. isotype-injected (9.5 ± 1.55 × 106 vs. 8.3 ± 0.7 × 106). Results are representative of 
at least 3 independent experiments.
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Figure 2: Anti-Slamf6 reduces tumor burden in LMP2A/λMyc bearing Rag1−/− mice. A. Expression of Slamf6 on 
CD19+CD20+ LMP2A/lMyc cells. B. Schematic outline of the experiment. Rag1−/− mice were i.p. injected with 1 × 106 cells and injected 
i.p. with 200 μg αSlamf6 or isotype control on day 7 and 14. Mice were sacrificed on day 19. C. Differences in spleen size and weight 
on day 19. A 3-fold reduction was observed in spleen weight of mice injected with αSlamf6 compared to isotype-injected group (0.066 
± 0.005 vs. 0.15 ± 0.01; p = 0.0008). D. Percentage of CD19+CD20+ LMP2A/λMyc tumors and absolute cell numbers in the spleen are 
shown. A 4-fold reduction in tumor burden was observed in αSlamf6-injected group (1.05 ± 0.17 × 106 vs. 4.07 ± 0.22 × 106; p < 0.0001). 
Representative of 2 independent experiments.
Figure 3: Treatment with αSlamf6 of TCL1-192 in the spleen, but not in the peritoneal cavity of SCID mice. A. Three 
weeks after transplanting TCL1-192 cells, SCID mice were injected with αSlamf6 or isotype mIgG2a once a week (Squares indicate the 
number of injections). Mice were monitored everyday. Whereas isotype treated mice died between 35-42 days, αSlamf6 injected mice were 
still alive on day 60, when the experiment ended (n = 5 mice each group). B. Schematic outline of the experiment indicating the timeline 
of i.p. injection of TCL1-192 cells and i.p. injections of 200 μg αSlamf6 (13G3) or the IgG2a isotype control on day 21 and 28. Mice were 
monitored by bleeding on days 21, 24 and 27 and were sacrificed on day 35. C. A 2.5-fold reduction in spleen size was caused in αSlamf6 
vs. isotype treated mice (0.55 ± 0.03 vs. 1.4 ± 0.08g; p = 0.0018) or 2.4-fold vs. untreated mice (1.303 ± 0.13 g; p < 0.0001) on day 35. 
The number of TCL1-192 cells was 3-fold reduced in αSlamf6 vs. isotype treated mice (3.4 ± 0.6 × 108 vs. 1.1 ± 0.1 × 109; p = 0.005) or 
4-fold vs. untreated mice (3.4 ± 0.6 × 108 vs. 1.36 ± 0.1 × 109 p = 0.0002). D. The number of TCL1-192 cells in the peritoneum of αSlamf6 
injected and isotype or non-injected SCID mice (3 ± 0.5 × 108 vs. 2.3 ± 0.5 × 108 and 3.1 ± 0.6 × 108 p = 0.8 and p = 0.4). The data are 
representative of 3 independent experiments. Results are representative of 4 independent experiments.
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In order to analyze the difference in leukemic 
burden between αSlamf6 and mIgG2a injected mice, 
αSlamf6 was administered only twice, i.e. on day 21 and 
day 28 after transplanting the TCL1-192 cells (outlined 
in Figure 3B). Mice were sacrificed on day 35 when the 
control group was moribund. On day 35, the spleen size 
of αSlamf6 treated mice was reduced 2.5 fold (Figure 3C) 
and the massive tumor infiltrate in the liver was absent in 
the αSlamf6 treated group compared to the two control 
groups (Supplementary Figure S4A). The total number of 
TCL1-192 cells in the spleen of αSlamf6 treated mice was 
significantly less than that of the control mice (Figure 3C). 
As in the prevention experiments, the leukemic cells from 
the peritoneal cavity were not affected by the monoclonal 
antibody (Figure 3D). The outcomes of these experiments 
indicate that treatment of existing tumors with two 
injections of αSlamf6 effectively eliminates TCL1-192 
cells in the spleen, but not in the peritoneum.
Anti-Slamf6 eliminates TCL1-192 cells in the 
blood of transplanted SCID mice
One week after the first injection of αSlamf6, i.e. on 
day 28, the number of B220+CD5+ TCL1-192 cells in the 
blood (Figure 4A Right panel and 4B) was lower than in 
control mice. However, at day 35, a week after the second 
injection, the number of TCL1-192 cells in the blood had 
increased in αSlamf6-injected mice, although it remained 
significantly lower than in the control mice (Figure 4A–
4C). This raises the possibility that on day 28 before the 
second αSlamf6 injection, αSlamf6-IgG from the first 
injection still occupied the receptor, which rendered the 
second injection of αSlamf6 ineffective (Figure 3B). This 
is indeed the case, because the Slamf6 receptor on the 
surface of the blood TCL1-192 cells was not accessible by 
a PE-conjugated αSlamf6 on 3 days after the first antibody 
injection [on day 24] and was only partially accessible on 
day 27, six days after the first injection (Supplementary 
Figure S3B). This is consistent with the half-life of mouse 
IgG2a of 6-8 days [40]. The data indicate that only the first 
injection of αSlamf6 was effective.
Distinct responses to αSlamf6 by the B220hiCD5hi 
and B220intCD5int TCL1-192 cell subsets
The dependence of the αSlamf6 antibody treatment 
on the location of the tumor cells prompted us to compare 
the key properties of the TCL1-192 cells in peritoneum, 
blood and spleen. Thirty-five days after transplant 
TCL1-192 cells in the peritoneum and spleen consisted 
primarily of a B220hiCD5hi sub-population, whereas both 
B220intCD5int and B220hiCD5hi cells were found in the 
blood (Figure 4A Left Panel). As the B220int CD5int TCL1-
192 cells are absent from the blood of αSlamf6 treated 
mice, this sub-population appears to have been eliminated 
by the antibody. By contrast, the B220hiCD5hi TCL1-192 
subpopulation appears resistant to the αSlamf6 treatment 
(Figure 4A and 4D).
These results prompted us to compare the state of 
activation, viability and signaling of the subpopulations 
in the blood of the treated and non-treated mice. 
Approximately half of the B220hiCD5hi TCL1-
192 subpopulation appears to be early apoptotic, as 
judged by Annexin-V/7-AAD staining (Figure 5A and 
Supplementary Figure S5A). By contrast, the B220intCD5int 
population, which is eliminated by αSlamf6, is Annexin-
V/7-AAD negative (Figure 5A).
The resistance of the B220hiCD5hi TCL1-192 
sub-population in the blood to αSlamf6 treatment also 
coincides with high expression of the BCR (Figure 5B). 
BCR proximal signaling, as judged by pSyk, pBtk and 
pPLCγ2, is also higher in the B220hiCD5hi population than 
in the B220intCD5int population of TCL1-192 cells (Figure 
5C). Expression of the chemokine receptor CXCR4 was 
significantly higher in the B220hiCD5hi subset than in the 
B220intCD5int subset (Figure 5B, Right Panel). Overall, 
the B220hiCD5hi population presents a mixture of cells, 
while some are undergoing apoptosis, remaining cells are 
on their way to migrating to secondary lymphoid organs, 
as suggested by their high BCR and CXCR4 expression 
levels [41].
The levels of pSyk, pBtk and pPLCγ2 were 
significantly lower in splenic TCL1-192 cells of αSlamf6 
treated mice compared to those in non-injected SCID 
mice (Figure 5D–5F and Supplementary Figure S5B). 
Interestingly, BCR signaling by peritoneal cavity TCL1-
192 cells differed from signaling by splenic tumor cells. 
Together, these findings suggest that the αSlamf6 antibody 
impacts the leukemic cells differently; most likely 
depending on the microenvironment in which the cells 
reside.
Administering αSlamf6 down-regulates proximal 
BCR signaling and induces ADCC
It is likely that the removal of leukemic cells in the 
blood involves αSlamf6-induced signaling in the TCL1-
192 cells, as well as cell mediated cytotoxicity (ADCC) 
by macrophages or NK cells [42]. To further assess the 
possibility that administering αSlamf6 instigates co-
stimulatory signaling networks in TCL1-192 cells, six 
doses of 200 μg/mouse of F(ab’)2 αSlamf6 were injected 
(outlined in Figure 6A). Although the leukemic burden 
was not affected (Figure 6B–6E), probably due to the 
short half life of the F(ab’)2 fragments in vivo, BCR 
signaling in spleen and peritoneum was observed (Figure 
6F–6H). In sum, the BCR signaling of TCL1-192 cells, 
which is induced by endogenous PtC [33], is affected by 
treatment of the CLL bearing SCID mice with αSlamf6.It 
would therefore appear that αSlamf6 regulates both BCR 
signaling through the Slamf6 receptor and efficiently 
induces ADCC.
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Absence of CLL cells in the peritoneal cavity 
after co-administering the BTK inhibitor 
ibrutinib
Although αSlamf6 antibody by itself is very 
effective in targeting the leukemic cells in blood, spleen 
and liver, it did not affect cells that reside in niches, e.g. 
the peritoneal cavity and omentum. Because macrophages 
and monocytes of the mouse peritoneal cavity are often 
found in lymphoid aggregates with T cells and CD5+B220+ 
B1 cells, which are almost absent in lymphoid tissues, 
we reasoned that the CLL cells resided in niches, which 
prevent efficient killing by αSlamf6 or other monoclonal 
antibodies [42]. Because in CLL patients the BTK 
inhibitor, ibrutinib, is known to release the tumor cells 
from their niches into the blood [43], we combined 
αSlamf6 treatment with administering ibrutinib.
Using the treatment protocol (Figure 3B), SCID 
mice injected with TCL1-192 were given 200 μg/mouse 
αSlamf6 and 25 mg/kg/day ibrutinib in the drinking water 
on day 21 (Figure 7A). Ibrutinib was kept in the drinking 
water until sacrifice and αSlamf6 was injected again on 
day 28. The number of leukemic cells in the blood was 
determined on day 20 and 27 (Figure 7A).
The spleen size and number of TCL1-192 cells 
was reduced 2-fold in αSlamf6 / ibrutinib-treated mice 
as compared to the number of splenocytes in animals 
that had been treated with αSlamf6 alone (Figure 7B and 
7C). As predicted, ibrutinib alone or αSlamf6 / ibrutinib 
efficiently eliminated TCL1-192 cells in the peritoneal 
cavity (Figure 7D).
Figure 4: The number of TCL1-192 cells is reduced in the blood of SCID mice upon treatment with αSlamf6. Schematic 
outline of the experiment is described in Figure 3B. A. Left Panel: Representative flow cytometry plot showing the overlay of B220+CD5+ 
cells from the peritoneum, blood and spleen. While TCL1-192 cells from the peritoneum, spleen and blood express comparable levels of 
high B220 and CD5; the blood contains a second population that expresses lower levels of B220 and CD5 (named B220intCD5int). Right 
Panel: Percentage of B220+CD5+ TCL1-192 cells in the blood of SCID mice at weeks 3, 4 and 5 in non-injected and αSlamf6 or mIgG2a 
injected groups. Representative gating for the two sub-populations (B220intCD5int and B220hiCD5hi) is depicted in the lower right corner for 
the isotype control group. B. On day 28, the total B220+CD5+ cell number per μl blood is a 100-fold less in αSlamf6-injected vs. mIgG2a 
injected mice (per μl blood: 0.6 ± 0.1 × 103 vs. 6 ± 1 × 104; p = 0.001); or 85-fold less as compared to the non-injected group (0.6 ± 0.1 × 
103 vs 5.1 ± 0.6 × 104; p = 0.0002). Although cells keep expanding by day 35, αSlamf6 injected group still has significantly less leukemic 
burden compared to mIgG2a injected (per μl blood: 7.5 ± 2.1 × 104 vs. 4.9 ± 0.7 × 105; p = 0.0015) vs. non-injected group (6.1 ± 0.7 × 
105; p = 0.0006). The data are representative of 3 independent experiments. C. Number of B220hiCD5hi leukemic cells in the blood of 
αSlamf6 treated mice is less than that in non-treated mice (0.63 ± 0.19 × 105 vs. 1.2 ± 0.1 × 105; p = 0.02). D. Mean Fluorescence Intensity 
(MFI) values of B220 and CD5 ex pression on B220hiCD5hi and B220intCD5int populations of the non-treated group at week 5. Results are 
representative of 4 independent experiments.
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Treatment with αSlamf6 / ibrutinib or αSlamf6 
reduced the number of TCL1-192 cells by 95% and 90%, 
respectively. Ibrutinib-treatment alone reduced the number 
of TCL1-192 cells by 70% (Figure 7E). As in Figure 4A, 
the Slamf6 resulted in the loss of B220intCD5int tumor 
cells, while ibrutinib did not differentially affect either 
sub-population.
The reduction of tumor cells in the bone marrow of 
αSlamf6 / ibrutinib treated animals was ten-fold, while 
αSlamf6 reduced the percentage of TCL1-192 cells only 
4.6 fold (Figure 7F). H&E staining indicated a complete 
absence of leukemic cells in the liver of αSlamf6 / 
ibrutinib-treated mice as compared to either αSlamf6 or 
ibrutinib alone (Supplementary Figure S4B).
To further show the efficacy of αSlamf6 and 
ibrutinib treatment on TCL1-192 cells, we employed in 
vitro assays using both splenic and peritoneal cells and 
measured viability (AnnexinV/7AAD negative) after 
72 hours of culturing with ibrutinib, αSlamf6 or both 
(Supplementary Figure S4C). In splenic TCL1-192 cells, 
ibrutinib or αSlamf6 alone led to a significant reduction 
in viability, and it was further reduced when the two 
compounds were combined. Interestingly, peritoneal cells 
were not affected by either treatment in vitro, suggesting 
Figure 5: Differential αSlamf6-dependent signaling in B220hiCD5hi and B220intCD5int TCL1-192 CLL cells in the blood, 
spleen and peritoneum. Schematic outline of the experiment is described in Figure 3B. A. Comparison of total B220+CD5+ cells in 
blood of the non-treated group (−) to its B220hiCD5hi subpopulation and B220hiCD5hi TCL1-192 cells in the αSlamf6-treated (+) mice by 
Annexin-V/7-AAD staining. B. MFI values of surface IgM (sIgM) and CXCR4 expression on B220hiCD5hi and B220intCD5int TCL1-192 
cells in the blood of αSlamf6-treated (+) and non-treated (−) mice. C. Proximal BCR signaling in B220hiCD5hi and B220intCD5int populations 
in the blood of αSlamf6-treated (+) and non-treated (−) mice was assessed by intracellular staining of pSyk, pBtk and pPLCγ2 and measured 
by flow cytometry. Representative of three experiments. D-F. Expression of pSyk, pBtk and pPLCγ2 in spleen and peritoneum. Results are 
representative of 4 independent experiments.
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that they are indeed more resistant to killing compared 
to splenic cells. This also indirectly suggests that in vivo, 
ibrutinib does remove the cells from the niche, rather than 
affecting their survival within the niche.
Taken together, the outcomes of these studies 
indicate that αSlamf6 and ibrutinib synergize in decreasing 
the overall leukemic burden.
Anti-human SLAMF6 reduces the number of 
human CLL cells
In order to support the findings with the murine 
TCL-1 model, we assessed responses to αhSLAMF6 of 
the human MEC-1 and OSU-CLL cell lines, which highly 
express SLAMF6 (Supplementary Figure S1). First, we 
transplanted 107 MEC-1 cells subcutaneously into [Rag 
x γc]−/− mice [44] before administering αhSLAMF6 or an 
isotype control (mIgG2b) on days 7 and 14 (Figure 8A).
Twenty-one days after transplanting the MEC-1 
cells, the volume of subcutaneous tumors in αhSLAMF6-
injected mice was 3.5 times smaller than that in 
isotype control mice (Figure 8A). This difference was 
already indicated on day 18 without reaching statistical 
significance. Because the [Rag x γc]−/− mice do not have 
NK cells, killing of MEC-1 tumors might be caused by 
macrophages via ADCC and possibly by αSLAMF6-
induced signaling.
We also tested the effect of the αhSLAMF6 antibody 
in combination with ibrutinib on apoptosis of in vitro 
cultured human OSU-CLL cells [37]. The combination of 
ibrutinib with αhSLAMF6 resulted in a higher percentage 
of Annexin-V+ cells (Figure 8B and 8C), once again 
Figure 6: Administering αSlamf6 F(ab’)2 fragments does not reduce the number of TCL1-192 cells. F(ab’)2 αSlamf6 
was generated using Pierce F(ab’)2 preparation kit. A. Outline of the experiment. TCL1-192 cells were i.p. injected on d0. On d7, d14 
and d21, 200 μg αSlamf6 (13G3) was i.p. injected, or on d7, d9, d14, d16, d21 and d23, 200 μg F(ab’)2 αSlamf6 was injected. Mice were 
sacrificed on d28. B. Differences in spleen size and weight in non-injected, αSlamf6 or F(ab’)2 αSlamf6 injected SCID mice on d28. C-E. 
Representative staining of B220+CD5+ from non-injected mice and number of B220+CD5+ cells in SCID mice after αSlamf6, F(ab’)2 
αSlamf6 injected were compared to those of non-injected mice in spleen, blood and peritoneum. Next, levels of pSyk F., pBtk G. and 
pPLCγ2 H. in TCL1-192 cells isolated on d28 from non-injected and F(ab’)2 αSlamf6 injected mice were compared. Representative of 2 
independent experiments with n = 9 mice total for F(ab’)2 αSlamf6 injected group. P values are as shown.
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Figure 7: Co-administering αSlamf6 with ibrutinib significantly reduces the number of TCL1-192 cells in the peritoneal 
cavity. A. Outline of the experiment. TCL1-192 cells were i.p. injected on d0. On d21, group of mice were either i.p. injected 
200 μg αSlamf6 (13G3), given 0.16 mg/ml ibrutinib in drinking water or was given both. Mice on ibrutinib received the drug 
until sacrifice. Mice received another injection of αSlamf6 on d28. Mice were sacrificed on d28. B. Differences in spleen size 
is as shown. C. Mice treated with a combination of αSlamf6 and ibrutinib had significantly smaller spleens and leukemic 
burden compared to αSlamf6-treated mice (weight: 0.31 ± 0.02 vs. 0.51 ± 0.04 g; p = 0.005 and a two-fold smaller number of 
TCL1-192 cells: 0.78 x108 ± 1.54 × 107 vs. 1.53 × 108 ± 1.76 × 107; p = 0.01) on day 35. D. Relative numbers of TCL1-192 
cells in the peritoneal cavity. BTK inhibitor resulted in 5.4 fold reduction in leukemic burden in peritoneal cavity compared 
to the control or αSlamf6 treated group alone (7.07 ± 1.43 × 107 vs. 3.82 ± 0.24 × 108; p < 0.0001). E. Representative FACS 
plots of B220+CD5+ in different groups and the exact cell numbers are as shown in the graph below. Ibrutinib alone treated 
mice resulted in 3-fold lower leukemic burden in blood compared to non-treated mice (per μl blood: 2.2 × 105 ± 2.9 × 104 vs. 
7.3 × 105 ± 7.7 × 104; p = 0.0003). However, αSlamf6 alone treated mice had significantly less TCL1-192 burden compared 
to ibrutinib alone group (0.67 × 105 ± 1.8 × 104; p = 0.0001). Difference in leukemic burden between αSlamf6 alone and 
ibrutinib/αSlamf6 treated group did not reach statistical significance (0.67 × 105 ± 1.8 × 104 vs. 0.27 × 105 ± 0.5 × 104; p = 
0.06). F. Percentage of TCL1-192 cells in the bone marrow. Anti-Slamf6 resulted in 4.6- fold reduction in percentage of TCL1-
192 cells in bone marrow compared to non-treated group (52.2 ± 4.4 vs. 11.2 ± 1.2%; p < 0.0001). When compared, αSlamf6 
in combination with ibrutinib resulted in a further reduction (2 fold) compared to αSlamf6 treatment alone (11.2 ± 1.2 vs. 5.6 
± 0.8%; p = 0.006). Representative of 2 independent experiments is shown. P values are as shown.
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suggesting a synergistic effect of the two agents on human 
CLL cell survival.
DISCUSSION
The pathogenesis of CLL is in part driven by 
signaling of the BCR in response to a restricted set of auto-
antigens, which might function both during precursor cell 
initiation and clonal progression. Disease aggressiveness 
has been correlated with the cell surface density and the 
kinetics of membrane microdomain formation of the BCR 
and its signaling networks [45, 46]. Whereas clinical 
trials with small molecules that target BCR initiated 
signaling, e.g. inhibitors of Syk [47], PI3K [48] and 
Btk [49], have been successful, monoclonal antibodies 
remain promising as therapeutic targets. Here we show 
that αSlamf6 efficiently eliminates the murine CLL clone 
TCL1-192, which after transplantation into SCID mice 
resides in the spleen and blood. We have chosen this 
TCL1-192 clone, because increased binding of its specific 
ligand PtC correlates with enhanced BCR signaling and 
cell proliferation in the spleen and lymph nodes, which 
correlates with observations in patients [33].
While αSlamf6 treatment causes a significant loss 
of leukemic cells in the blood and spleen of TCL1-192-
bearing SCID mice, as well as LMP2A/λMyc bearing 
Rag1−/− mice, both tumor cells remain in the peritoneal 
cavity of the recipient animals. The Chiorazzi lab 
discovered that the tumor microenvironments, e.g. 
spleen vs. peritoneal cavity, influences the way TCL1-
192 cells respond to antigenic stimuli and BCR signaling 
[33]. It is therefore plausible that the αSlamf6 antibody 
does not affect peritoneal TCL1-192 cells, because of the 
protective microenvironment and altered signaling of the 
leukemic cells in the peritoneal cavity. In support of this 
concept is that administering Rituximab (αCD20) does 
not remove B220+CD5+ B1a cells from the peritoneal 
cavity, while it is very efficient in the killing of B cells 
in most tissues [42]. Impaired Fc-receptor functions 
have been implicated [42]. Similarly, CD5+ B1 cells 
Figure 8: Anti-human SLAMF6 affects progression of human MEC-1 and OSU CLL cells in vitro and in vivo. A. 107 
MEC-1 cells were subcutaneously injected into Rag2−/−γc−/− mice. 200μg/ml mouse αhuman-SLAMF6 or isotype mIgG2b was injected 
i.p. on day 7 and 14 (Left Panel). Tumor volume was determined by measuring 3 diameters at indicated time points (Right Panel). B-C. 
OSU-CLL cells were cultured in vitro in the presence of 50 μg/ml Fc-crosslinker alone, 10 μg/ml mouse αhSLAMF6 and Fc-crosslinker, 0.5 
μM ibrutinib or in combination for 72 hours and apoptosis was measured by Annexin-V+/PI-. B. The plots demonstrate the representative 
gating strategy for AnnexinV/PI staining. Results are representative of 3 independent experiments. (*: p < 0.05, **: p < 0.01, ***: p < 0.005)
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respond differently to BCR stimuli in the peritoneum of 
WT mice than that in the spleen due to expression of the 
Src kinase Lck, which renders peritoneal B1 cells hypo-
responsive [50–52]. Interestingly, most human CLL cells 
express Lck albeit at varying levels [53]. Importantly, 
the outcomes of several studies indicate that some CLL 
patients have massive ascites, suggesting that the tumor 
cells in the peritoneal cavity may not respond to some 
treatment protocols [54].
We find that in the blood two sub-populations of 
mouse TCL1-192 CLL cells exist, i.e. IgMhi / CXCR4hi 
/ B220hiCD5hi and IgMlow / CXCR4low / B220intCD5int 
TCL1-192 cells. Coelho et al. [41] suggest that 
IgMlow patient-derived CLL cells have just entered the 
circulation, as the low levels of BCR are caused by 
antigenic exposure within tissues. By contrast, cells 
that have been in circulation longer display a higher 
BCR expression [41]. A plausible interpretation of 
our observations is therefore that IgMlow / CXCR4low 
/ B220intCD5int TCL1-192 cells are entering into the 
circulation from the peritoneal cavity, spleen or other 
secondary lymphoid organs. Administering αSlamf6 
eliminates this IgMlow / CXCR4low / B220intCD5int TCL1 
subset in the blood. While half of the IgMhi / CXCR4hi 
/ B220hiCD5hi cells are in the process of apoptosis as 
judged by the Annexin-V staining, the other half of 
this sub-population is possibly on its way to migrating 
to other tissues for antigenic stimulation [41]. 
Alternatively, the pro-apoptotic B220hiCD5hi population 
may already have undergone cell membrane damage, 
thus not allowing proper binding of the antibody for 
efficient targeting. Expression levels of CXCR4 support 
the concept, as this chemokine receptor is not only a 
migration marker, but is also involved in apoptosis of 
CLL and acute myeloid leukemia cells [55, 56].
Administering a combination of αSlamf6 and 
ibrutinib eliminated TCL1-192 tumors in the recipient 
SCID mice due to a synergistic effect, which was 
greater than caused by each agent alone. The most 
likely explanation is that ibrutinib down-regulates BCR 
signaling and causes apoptosis of the tumor cells within 
the peritoneum and elsewhere in the body. Second, as 
ibrutinib is known to move CLL cells out of their various 
niches into the circulation and removal of leukemic cells 
from the peritoneal cavity could have resulted in this 
synergistic reduction of the overall tumor burden. Our 
use of αhSLAMF6 in in vitro and in vivo systems using 
CLL cell lines support the potential of the antibody as 
a therapeutic target and deserves further investigation 
using primary CLL cells. Thus, the outcomes of this 
study suggest that αSLAMF6 and ibrutinib should 
be considered as a combination therapy for CLL and 
possibly other SLAMF6 expressing B cell tumors.
MATERIALS AND METHODS
Mice
CB17 SCID and Rag2−/−γc−/− mice from Taconic 
(Hudson, NY) and Rag1−/− mice from the Jackson 
Laboratory are maintained under specific pathogen-free 
conditions at the Beth Israel Deaconess Medical Center 
(BIDMC) animal facility. Experiments were performed 
according to the guidelines of the Institutional Animal 
Care and Use Committee (IACUC) at BIDMC.
CLL cells
Peripheral blood samples were obtained after 
informed consent from CLL patients at BIDMC, 
Department of Hematology/Oncology. Patient consent 
for samples used in this study was obtained in accordance 
with the Declaration of Helsinki on protocols that were 
approved by the Institutional Review Board at BIDMC. 
Peripheral blood mononuclear cells (PBMCs) were 
isolated using lymphocyte separation medium (Corning, 
Manassas, VA).
The human CLL MEC-1 cell line [36] was a gift 
from Dr. Silvia Deaglio (University of Turin, Italy). Cells 
were cultured in RPMI 1640 medium, as described [57]. 
The human OSU-CLL cell line [37], which was generously 
donated by Dr. John C. Byrd (Ohio State University), was 
cultured as described.
The leukemic TCL1-192 clone (B6xC3H) was 
generated as described [33]; it’s BCR recognizes 
phosphatidylcholine (PtC) with a single IgHV-D-J 
rearrangement.
Flow cytometry
PBMCs from CLL patients, the MEC-1 and 
OSU-CLL cell lines were stained with: PE, FITC or 
APC conjugated anti-human monoclonal antibodies 
were purchased from Biolegend (San Diego, CA): CD3 
(HIT3a), CD19 (HIB 19), CD5 (UCHT2), SLAMF1 
(A12), SLAMF2 (BJ40), SLAMF3 (Hly-9.1.25), 
SLAMF4 (C1.7), SLAMF5 (CD84.1.21), SLAMF6 (NT-
7), SLAMF7 (162.1), PE-anti-mouse mIgG1 (MOPC-
21), anti-mIgG2a (MOPC-173) and anti-mIgG2b isotype 
controls (MPC-11). Anti-human SLAMF8 (250014) was 
from R&D Systems (Minneapolis, MN). SLAMF surface 
expression on CLL cells from 57 patients was determined 
with antibodies provided by the “Ninth International 
Workshop on Leukocyte Antigens” [22].
Dead cells were excluded by DAPI staining 
and cell count per μl of blood was determined by 
CountBright absolute counting beads (Life Technologies, 
Carlsbad, CA).
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PE, FITC, APC, APC/Cy7, PerCP/Cy5.5, PE/Cy7 
or Pacific blue conjugated anti-mouse antibodies were 
purchased from Biolegend: B220 (RA3-6B2), Slamf1 
(TC15-12F12.2), Slamf2 (HM48-1), Slamf3 (Ly9ab3), 
Slamf5 (mCD84.7), Slamf6 (330-AJ), IgM (RMM-1) and 
CXCR4 (L276F12). Anti-mouse CD5 (53-7.3) and Slamf4 
(eBio244F4) antibodies were purchased from eBioscience 
(San Diego, CA). Anti-mouse Slamf7 (520914) antibody 
was purchased from R&D Systems (Minneapolis, MN).
For intracellular staining with the BD Cytofix/
Cytoperm Kit, the following antibodies were used: 
pZAP70/pSyk(Y319/Y352) (n3kobu5) and pBtk(Y551/
Y511) (M4G3LN) from eBioscience and pPLCγ2(Y759) 
(K86-689.37) from BD Biosciences (San Jose, CA). The 
procedure described in the manufacturer’s manual was 
followed.
The Annexin-V Apoptosis Kit was purchased from 
eBioscience.
The cells were acquired on a BD LSRII flow 
cytometer and data analysis was performed using FlowJo 
software (Tree Star Inc., Ashland, OR).
LMP2A/λMyc tumor cells
Peripheral lymph node tumor cells from LMP2A/
λMyc (Tg6/λMyc) mice [35] were i.p. injected into 
Rag1−/− mice.
Histology
Liver sections were fixed in 10% formalin and 
stained with H&E at the BIDMC histology core.
Reagents
The mouse monoclonal αSlamf6 (clone 13G3) 
hybridoma was generated from spleens of Slamf6−/− mice 
immunized with WT thymocytes [26]. Hybridomas were 
used to produce IgG2a by Harlan Laboratories (South 
Easton, MA). Mouse IgG2a (C1.18) isotype control was 
purchased from BioXcell, Inc. (West Lebanon, NH). 
Mouse anti-human SLAMF6 antibody (994.1) was 
obtained from ARCA Biopharma (Westminster, CO).
F(ab’)2 goat anti-mouse IgG was purchased from 
Jackson Immunoresearch.
The BTK inhibitor, ibrutinib, was purchased from 
ChemieTek (Indianapolis, IN). Ibrutinib was dissolved in 
DMSO and prepared as described elsewhere [49].
In vitro culturing of OSU-CLL
5 × 104 OSU-CLL cells were seeded in 96-well 
flat bottom plate. Relevant wells received 50 μg/ml Fc-
crosslinker, 10 μg/ml αSLAMF6 or 0.5 μM ibrutinib. Plate 
was incubated for 72 hours at 37C and 5% CO2. Viability 
was measured by Annexin-V/PI staining.
Injection of MEC-1 in [Rag x gc]-/-  mice
107 MEC-1 cells were injected subcutaneously into 
[Rag x γc]−/− (Taconic) mice and monitored as previously 
described [44].
Statistics
Statistical analyses were calculated using GraphPad 
Prism software (GraphPad, La Jolla, CA). The Student t 
test or 2-way ANOVA was used to compare groups; results 
are represented as mean ± SD. P < 0.05 was considered 
significant.
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